YM encouraged by nimotuzumab results

YM BioSciences (AMEX:YMI; TSX:YM) has released results at the ASCO conference from a randomized Phase 2 gastric cancer study of its nimotuzumab drug conducted by its licensees, Daiichi Sankyo in Japan and Kuhnil Pharma in Korea. “The overall findings of the study are positive and support the promise of nimotuzumab in this important global cancer [...]

YM BioSciences expands trial for CYT387

YM BioSciences (AMEX:YMI;TSX:YM) has expanded the Phase 1/2 clinical trial for its oral JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis to five clinical sites and has extended the trial protocol to allow patients who have derived a clinical benefit to continue to receive treatment beyond the nine cycles of the core protocol. “The initiation of [...]

YM posts significant response rates with JAK 1/JAK 2 Inhibitor

YM BioSciences‘ (AMEX:YMI;TSX:YM) data from the initial portion of the Phase 1/2 trial of its JAK1/JAK2 Inhibitor, CYT387, demonstrated “substantial activity” in reducing spleen size and controlling constitutional symptoms, as well as improving anemia in a considerable number of patients with myelofibrosis. “This additional benefit could significantly differentiate our JAK1/JAK2 inhibitor from others in development, [...]

YM names Glover as CEO

YM BioSciences (AMEX:YMI;TSX:YM) has appointed Dr. Nick Glover, currently president and COO, to the added post of CEO, effective with the annual meeting Nov. 18, succeeding David Allan, who will continue as chairman. “Given the rapid progress being made with our recently acquired CYT387 JAK inhibitor program, the ongoing advancement of nimotuzumab globally, and the [...]

YM results published in British Journal of Cancer

Phase 1 results for YM BioSciences‘ (AMEX:YMI;TSX:YM) CYT997 drug candidate, demonstrating it was well-tolerated at doses associated with pharmacodynamic evidence of vascular disruption in tumours, have been published in the British Journal of Cancer. CYT997, which is designed to damage or inhibit formation of tumour blood vessels, is currently in a Phase 2 clinical trial [...]

YM gets orphan drug status for JAK1/2 drug

The FDA has granted orphan drug status to YM BioSciences’ (TSX:YM; AMEX:YMI) JAK1/2 inhibitor, CYT387, for the treatment of myelofibrosis, in which a patient’s bone marrow is replaced by scar tissue, and for which treatment options are limited or unsatisfactory. The designation provides YM with seven years of U.S. marketing exclusivity, tax credits for clinical [...]

YM reshuffles the Cytopia deck

YM BioSciences (AMEX:YMI; TSX:YM) got more than it bargained for with its recent acquisition of Australia’s Cytopia. “When we were buying the company, our sole interest was in CYT997, Cytopia’s lead vascular disrupting agent (VDA),” CEO David Allan told biotuesdays.com in an exclusive interview.  VDAs, which can disrupt the blood flow that feed tumours, became [...]